FLINDERS TECHNOLOGIES PTY. LTD.
|FLINDERS TECHNOLOGIES PTY. LTD. Patent applications|
|Patent application number||Title||Published|
|20090209432||Detecting targets using nucleic acids having both a variable region and a conserved region - The invention relates to nucleic acid molecules for use in detecting a target nucleic acid molecule which is a member of a class of nucleic acid molecules and which is characterised by a specific variant region, said nucleic acid molecule comprising (i) a nucleic acid stem region which comprises a nucleic acid interaction site directed to a conserved region of the class of which said target nucleic acid molecule is member, or part thereof and which conserved region is located proximally to a variant region; operate y linked to (ii) a nucleic acid recognition region comprising at least two nucleotides. The nucleic acids are used in arrays and are an efficient means of screening molecules exhibiting a unique nucleotide sequence within a randomly varying population. The invention is useful in monitoring the effectiveness of therapeutic drug therapies and the progression of medical conditions, characterised by the presence of clonal populations of cells, particularly clonal lymphocyte populations.||08-20-2009|
|20080268433||Use of Mitochondrial Point Mutations as Sensitive Clonal Markers - The present invention relates to a method of detecting an aberrant population of cells in a subject and, more particularly, to a method of qualitatively and/or quantitatively detecting a clonal population of aberrant cells in a subject by ‘screening for mitochondrial DNA mutations. The method of the present invention is useful in a range of applications including, but not limited to, diagnosing a condition characterised by the presence of a clonal population of aberrant cells (such as a neoplastic condition), monitoring the progression of such a condition, predicting the likelihood of a subject's relapse from a remissive state to a disease state or for assessing the effectiveness of existing therapeutic drugs and/or new therapeutic agents. In a related aspect, the present invention also provides a method of characterising clonal populations of aberrant cells by determining the nature and range of mitochondrial DNA mutations expressed by a specific population of aberrant cells.||10-30-2008|